<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">Before clinical manifestations for COVID-19, a significant viral amplification occurs, which subsequently leads to mild symptoms. Later, at the end stage of infection, severe symptoms are mostly due to the inflammatory cell infiltration and inflammatory cytokine storm, which cause acute lung injury, ARDS, and death (
 <xref rid="bib71" ref-type="bibr">Zhang et al., 2020c</xref>). Accordingly, the treatment strategy depends on the stage of the disease or a combination therapy might be considered. Also, it has been suggested that the drugs with both antiviral and anti-inflammatory properties could be taken into account for COVID-19 clinical trials including baricitinib, ruxolitinib, and fedratinib (
 <xref rid="bib54" ref-type="bibr">Stebbing et al., 2020</xref>).
</p>
